Recombinant goat pox virus, construction method and application thereof

By constructing the recombinant goat pox virus expressing LSDV 132 protein, the problems of insufficient protection of existing vaccines and the risk of virus spread are solved, and efficient and safe development of cattle nodule skin disease vaccines have been achieved.

CN120249229APending Publication Date: 2025-07-04LANZHOU VETERINARY RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES(LANZHOU BRANCH CENTER OF CHINA ANIMAL HEALTH & EPIDEMIOLOGY CENTER)
1 Cites 0 Cited by

Patent Information

Application Number
CN202510435335.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-04-08
Publication Date
2025-07-04

AI Technical Summary

Technical Problem

The existing live attenuated vaccines are insufficient in preventing skin diseases of cattle nodules, and have adverse reactions and risk of viral spread. It is difficult to insert the LSDV ORF132 gene into goat pox virus through direct enzyme cleavage.

Method used

A recombinant shuttle plasmid expressing LSDV 132 protein was constructed. The goat pox virus vaccine strain GTPV-AV41 was used as a vector to insert the TK gene into the target, and the recombinant virus was constructed through homologous recombination. The GFP gene was deleted through the Cre/loxp recombination system, and the recombinant goat pox virus that stably expressed the LSDV 132 protein was screened out.

Benefits of technology

The recombinant goat pox virus rGTPV-TK-750-1 with high genetic stability and high virus content was obtained. High levels of antibodies were produced after immunization, with a percentage protection and no detoxification phenomenon, and good safety, laying the foundation for the development of the cattle nodule skin disease vaccine.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention belongs to the field of biology, and particularly relates to a recombinant goat pox virus as well as a construction method and application thereof. The method comprises the following steps: constructing a donor vector pGTPV-132LSDV-F2A-1322-P2A-GFP by utilizing a DNA (Deoxyribonucleic Acid) recombination technology, and then constructing a recombinant goat pox virus rGTPV-TK-750-1 (rGTPV-132) for stably expressing the LSDV 132 protein by taking a GTPV vaccine strain (AV41) as a framework and a TK gene as an insertion target spot through homologous recombination; the recombinant goat pox virus rGTPV-132 can stably express the LSDV 132 protein, has good hereditary stability and high virus titer, can be used as a strain for vaccine production, and lays a foundation for research, development and application of vaccines for preventing LSDV.
Need to check novelty before this filing date? Find Prior Art